International Conference on Oncology & Hematology
  • Follow

Accepted Abstracts

Systemic lupus erythematosus female with (diffuse large B-cell) non-hodgkin’s lymphoma

Abeer Alharbi*1, Mohammed Salem2, Omer Alharbi3, Mohammed Abdaljawad3, Ahmed Alhujaliy3

1 Chest and Sleep Medicine Consultant, KSA
2 Ibn Sina Medical College, KSA
3 King Fahad Hospital, KSA

Citation: Alharbi A, Salem M, Alharbi O, Abdaljawad M, Alhujaliy A (2019) Systemic lupus erythematosus female with (diffuse large B-cell) non-hodgkin’s lymphoma. SciTech Oncology 2019. Dubai: UAE

Received: March 07, 2019         Accepted: March 09, 2019         Published: March 11, 2019

Abstract

 

Systemic lupus erythematosus (SLE) is an autoimmune disease with multisystem complications arising from both underlying disease activity and therapy-related side effects. SLE’s association with lymphoma is a well-established phenomenon. Studies have reported a higher incidence of lymphoma in the SLE population compared with healthy cohorts. A 45-year-old woman with SLE presented with fever, cough, sputum, loss of appetite, and fatigue for 4 months. Before that time, her (SLE) symptoms had been well controlled on hydroxychloroquine, azathioprine, and small dose prednisone. Physical examination at initial evaluation was remarkable for bilateral inspiratory crackles. Laboratory investigations were normal. Chest X-ray ,and Computed tomography to chest showed bilateral cavitary pulmonary nodules and masses. Bronchoscopy with transbronchial biopsy was done. The histopathology with Immunohistochemistry done, tumor cells are positive for CD45, CD20, and bcl-2 negative pan for pan CK, CD 56, bcl-6, CD 10, and Tdt. CD 3 highlights the cell population. k67 index is >80. The  diagnosis  of  diffuse large B-cell non-Hodgkin’s lymphoma  was made. The patient referred to oncology service, where they started her on 4 cycles of R-CHOP by followed 4 cycles of high-dose chemotherapy. She underwent hematopoietic stem cell transplantation and achieved complete remissions for both SLE ,and here malignancy.